Brought to you by 
Arcus Biosciences closes $107mm Series C round
14 Nov 2017
Executive Summary
Arcus Biosciences Inc. (cancer immunotherapies) raised $107mm through its Series C round. GV (formerly Google Ventures) led and was joined by new investors Wellington Management, EcoR1 Capital, BVF Partners, Decheng Capital, Hillhouse, Aisling Capital, and entities affiliated with Leerink Partners. Returning backers The Column Group, Foresite Capital, Invus Opportunities, DROIA, Celgene, and Taiho Ventures also participated. The round will support continued development of Phase I projects AB928 (dual adenosine receptor antagonist) and AB122 (PD-1 antibody), as well as preclinical candidates AB680 (CD73 inhibitor) and AB154 (TIGIT antibody).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arcus Biosciences closes $107mm Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice